Navigation Links
Vasomedical Reports Financial Results for the Quarter Ended November 30, 2010
Date:1/18/2011

WESTBURY, N.Y., Jan. 18, 2011 /PRNewswire/ -- Vasomedical, Inc. ("Vasomedical") (OTC Bulletin Board: VASO), a global provider of medical devices, today announced financial results of the three months ended November 30, 2010. Vasomedical is a world leader in the noninvasive treatment of cardiovascular diseases. In addition, the Company, through a wholly-owned subsidiary Vaso Diagnostics d/b/a VasoHealthcare, commenced operations on July 1, 2010 under its sales representative agreement with GE Healthcare (the "GEHC Agreement") for the sale of select GE Healthcare Diagnostic Imaging products. Under the GEHC Agreement, VasoHealthcare has been appointed the exclusive representative for these products to specific market segments in the 48 contiguous states of the United States and the District of Columbia.

For the second quarter ended November 30, 2010, the Company's total revenues were $3.801 million, an increase of $2.961 million, or 353% as compared to revenues of $0.839 million for the same quarter last year. Revenue in the equipment segment of our business increased 113% to $1.789 million for the three-month period ended November 30, 2010 as compared to $0.839 million for the comparable prior period. The Company reported an operating loss of $1.153 million for the quarter, compared to an operating loss of $0.314 million for the same period in the prior fiscal year. This loss was attributable to an operating loss of $1.271 million in the sales representation segment, which was partially offset by an operating profit of $0.168 million in our equipment segment.

The Company is required, under certain accounting rules, to defer the recognition of revenues until the underlying equipment or service is accepted or performed, which may take several quarters. Jonathan Newton, Chief Financial Officer of the Company, stated that, "we record GEHC commissions initially as deferred revenue, and we recognize commission revenue generally when the related equipment is delivered and accepted per the terms of the GEHC Agreement. As a result, our expenses in the sales representation segment will precede the related revenue in the early stages of its operation." As of November 30, 2010, the Company had approximately $6.597 million in total deferred revenue, an increase of $5.570 million from six months ago.

Commenting on the performance of VasoHealthcare, Brent Barron, subsidiary President and Chief Operating Officer, noted, "We are very pleased with the significant achievements of our sales professionals during the first few months of operation. We believe that we have met or exceeded every initial strategic and financial objective and expect to deliver exceptional performance under our agreement with GE Healthcare. Our level of accomplishment in this initial stage of our agreement should serve as a foundation for a sustainable long-term relationship."

"Our equipment and sales representation segments both have delivered excellent performance in the quarter," said Dr. Jun Ma, President and Chief Executive Officer of Vasomedical. "The fact that EECP® system sales more than doubled from a year ago is a testimonial both to the success of our efforts to expand EECP® systems sales in the international market and to the growth of our direct sales force in the U.S. The superior execution of our VasoHealthcare business, which has resulted in exceeding the planned target in a difficult economic climate, further enhances our belief of a bright future for the Company."

About Vasomedical

Vasomedical, Inc. is primarily engaged in designing, manufacturing, marketing and supporting EECP® external counterpulsation systems based on the Company's proprietary technology. EECP® therapy is a non-invasive, outpatient therapy for the treatment of diseases of the cardiovascular system currently indicated for use in cases of angina, cardiogenic shock, acute myocardial infarction and congestive heart failure. The therapy serves to increase circulation in areas of the heart with less than adequate blood supply and may restore systemic vascular function. The Company provides hospitals, clinics and private practices with EECP® equipment, treatment guidance and a staff training and maintenance program designed to provide optimal patient outcomes. EECP® is a registered trademark for Vasomedical's enhanced external counterpulsation system. Through its sales representative agreement with GE Healthcare, the Company is also engaged as an exclusive sales representative for certain GE Healthcare products. Additional information is available on the Company's website at www.vasomedical.com.

VasoHealthcare™, a wholly owned subsidiary of Vasomedical Inc. is a professional sales representation company offering vendors an alternative third party sales channel. Additional information is available at www.vasohealthcare.com.

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as "anticipates", "believes", "could", "estimates", "expects", "may", "plans", "potential" and "intends" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments. Contact:Dr. Jun Ma or Jonathan NewtonVasomedical, Inc.516-997-4600customerservice@vasomedical.com
'/>"/>

SOURCE Vasomedical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vasomedical Announces Launch of Its Online Company Store
2. Dan Rather Reports Investigates our Heavy Dependence on Antibiotics - What are the Causes... and the Consequences?
3. Questcor Pharmaceuticals Reports Strong Finish to 2010
4. Auxilium Pharmaceuticals Reports Preliminary Fourth Quarter 2010 Net Revenue and Announces 2011 XIAFLEX Revenue Guidance
5. Pharmasset Reports Positive Results from its HCV Clinical Programs
6. Michigan Pre-Seed Capital Fund Reports Investments Totaling $2.5 Million in 2010
7. Topical China Industries Research Reports Published at MarketPublishers.com
8. Consumer Reports Health News
9. American Pacific Reports Fiscal 2010 Results
10. New Topical Research Reports by iData Research Published by MarketPublishers.com
11. Biodel Reports Fourth Quarter and Fiscal Year 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... 12, 2016 On Thursday, Feb. 11, 2016, ... St. David,s North Austin Medical Center successfully completed the ... Xi ® Surgical System with Trumpf Medical,s advanced ... Thiru Lakshman , M.D., colorectal surgeon at the Texas ... Integrated Table Motion technology, which seamlessly combines the da ...
(Date:2/12/2016)... , Feb. 12 2016  OMS Supply, a large ... medical practitioners, announced today the recent launching of their ... a variety of features that enhance the user experience ... supplies. --> --> ... fairly new company that started in early 2016, they ...
(Date:2/12/2016)... --> ... Global Clinical Trials Review, H2, 2015 provides an ... trials landscape along with top level data related ... & E7), Trial Status, Trial Phase, Sponsor Type ... involved and enlists all trials (Trial title, Phase, ...
Breaking Medicine Technology:
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... ... Infusion Nurses Society (INS) states that vein visualization technology should be used to ... healthcare facilities around the world, the INS Standards mandate the use of vein ...
(Date:2/12/2016)... ... February 12, 2016 , ... According to an article published February ... a significant portion of hernia repairs throughout the United States. Commenting on this article, ... notes that this trend has not only been expected, but it seems to be ...
(Date:2/12/2016)... , ... February 12, 2016 , ... CDRH Enforcement Trends: , Back to the Future ... , As Winston Churchill said, “Those who don’t learn from history are doomed ... to expect when they come knocking this year. But that takes time. , Take ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... announced that nominations have closed for the ISE Southeast Awards 2016. Finalists and ... announced at the ISE® Southeast Executive Forum and Awards Gala on March 15, ...
(Date:2/12/2016)... ... ... AssureVest Insurance Group, a locally owned insurance firm with offices serving Washington NC ... to purchase computers and software for Mrs. Harrison’s 2nd and 3rd grade special needs ... area and has more than 60 2nd and 3rd graders with learning disabilities. A ...
Breaking Medicine News(10 mins):